Gilotrif Approval History
- FDA approved: Yes (First approved July 12, 2013)
- Brand name: Gilotrif
- Generic name: afatinib
- Dosage form: Tablets
- Company: Boehringer Ingelheim Pharmaceuticals, Inc.
- Treatment for: Non-Small Cell Lung Cancer
Gilotrif (afatinib) is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Development History and FDA Approval Process for Gilotrif
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.